Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics announced significant progress at its 2025 Annual General Meeting, ...
In an exclusive interview, Alterity Therapeutics’ ( ATHE) CEO David Stamler met with The Fly to discuss the company, the biotech industry, ongoing trials, upcoming milestones and much more. Published ...
Alterity Therapeutics’ phase II study of its lead compound ATH434 in multiple system atrophy (MSA) has been featured in an oral presentation at the American Autonomic Society (AAS) 36th International ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
The citations MacMullen et al., 2017, Irmady et al., 2023, and Beghini et al., 2021 were erroneously included at certain points in the section Methods, Bioinformatics and statistical analysis. This ...
Background: The familial association of psoriasis with multiple sclerosis (MS) has been observed in several international studies. Whether this link is applicable in an Australian setting has yet to ...
The α-synuclein protein can adopt several different conformations that cause neurodegeneration. Different α-synuclein conformers cause at least three distinct α-synucleinopathies: multiple system ...
The go-live of NAFIS NextGen in Australia marks IDEMIA Public Security's first international cloud-based ABIS deployment and sets a new benchmark for cloud-based biometric identification systems ...
Australian pensions are working to create a platform to share information on criminal activity including cyber threats to help thwart potential attacks, the Australian Financial Review reported The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback